

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measures**

<i>(Dollars in Millions Except Per Share Data)</i>	Third Quarter		% Incr. / (Decr.)	Nine Months YTD		% Incr. / (Decr.)
	2014	2013		2014	2013	
Earnings before provision for taxes on income - as reported	\$ 6,810	3,667	85.7 %	\$ 17,860	12,721	40.4 %
Ortho-Clinical Diagnostics divestiture net gain	(1,948)	-		(1,948)	-	
Litigation expenses	285	872		561	1,776	
Additional year of Branded Prescription Drug Fee	220	-		220	-	
Synthes integration/transaction costs	167	122		429	502	
In-process research and development	-	178		22	242	
DePuy ASR™ Hip program	126	35		126	117	
Other	-	(43)		-	(98)	
Earnings before provision for taxes on income - as adjusted	<u>\$ 5,660</u>	<u>4,831</u>	<u>17.2 %</u>	<u>\$ 17,270</u>	<u>15,260</u>	<u>13.2 %</u>
Net Earnings - as reported	\$ 4,749	2,982	59.3 %	\$ 13,802	10,312	33.8 %
Ortho-Clinical Diagnostics divestiture net gain	(1,149)	-		(1,149)	-	
Litigation expenses	231	720		573 (1)	1,419	
Additional year of Branded Prescription Drug Fee	220	-		220	-	
Synthes integration/transaction costs	130	103		318	373	
In-process research and development	-	126		16	168	
DePuy ASR™ Hip program	111	31		111	122	
Tax benefit associated with Conor Medsystems	-	-		(398)	-	
Other	-	(43)		-	(79)	
Net Earnings - as adjusted	<u>\$ 4,292</u>	<u>3,919</u>	<u>9.5 %</u>	<u>\$ 13,493</u>	<u>12,315</u>	<u>9.6 %</u>
Diluted Net Earnings per share - as reported	\$ 1.66	1.04	59.6 %	\$ 4.81	3.58	34.4 %
Ortho-Clinical Diagnostics divestiture net gain	(0.40)	-		(0.40)	-	
Litigation expenses	0.08	0.25		0.19	0.49	
Additional year of Branded Prescription Drug Fee	0.08	-		0.08	-	
Synthes integration/transaction costs	0.04	0.04		0.11	0.13	
In-process research and development	-	0.04		0.01	0.06	
DePuy ASR™ Hip program	0.04	0.01		0.04	0.04	
Tax benefit associated with Conor Medsystems	-	-		(0.14)	-	
Other	-	(0.02)		-	(0.02)	
Diluted Net Earnings per share - as adjusted	<u>\$ 1.50</u>	<u>1.36</u>	<u>10.3 %</u>	<u>\$ 4.70</u>	<u>4.28</u>	<u>9.8 %</u>

(1) Includes adjustment to deferred tax asset related to deductibility by tax jurisdiction

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.